Increased rigidity of the chiral centre of tocainide favours stereoselectivity and use-dependent block of skeletal muscle Na+ channels enhancing the antimyotonic activity in vivo

Talon S, De Luca A, De Bellis M, Desaphy JF, Lentini G, Scilimati A, Corbo F, Franchini C, Tortorella P, Jockusch H, Camerino DC (2001)
BRITISH JOURNAL OF PHARMACOLOGY 134(7): 1523-1531.

Download
Es wurde kein Volltext hochgeladen. Nur Publikationsnachweis!
Zeitschriftenaufsatz | Veröffentlicht | Englisch
Autor
; ; ; ; ; ; ; ; ; ;
Abstract / Bemerkung
1 Searching for the structural requirements improving the potency and the stereoselectivity of Na+ channel blockers as antimyotonic agents, new derivatives of tocainide, in which the chiral carbon atom is constrained in a rigid alpha -proline or pyrrolo-imidazolic cycle, were synthesized as pure enantiomers. 2 Their ability to block Na+ currents, elicited from -100 to -20 mV at 0.3 Hz (tonic block) and 2-10 Hz (use-dependent block) frequencies, was investigated in vitro on single fibres of frog semitendinosus muscle using the vaseline-gap voltage-clamp method. 3 The alpha -proline derivative, To5, was 5 and 21 fold more potent than tocainide in producing tonic and 10 Hz-use-dependent block, respectively. Compared to To5, the presence of one methyl group on the aminic (To6) or amidic (To7) nitrogen atom decreased use-dependence by 2- and 6-times, respectively. When methylene moieties were present on both nitrogen atoms (To8), both tonic and use-dependent block were reduced. 4 Contrarily to tocainide, all proline derivatives were stereoselective in relation to an increased rigidity. A further increase in the molecular rigidity as in pyrrolo-imidazolic derivatives markedly decreased the drug potency with respect to tocainide. 5 Antimyotonic activity, evaluated as the shortening of the time of righting reflexes of myotonic adr/adr mice upon acute drug in vivo administration was 3 fold more effective for R-To5 than for R-Tocainide. 6 Thus, constraining the chiral centre of tocainide in alpha -proline cycle leads to more potent and stereoselective use-dependent Na+ channel blockers with improved therapeutic potential.
Erscheinungsjahr
Zeitschriftentitel
BRITISH JOURNAL OF PHARMACOLOGY
Band
134
Ausgabe
7
Seite(n)
1523-1531
ISSN
eISSN
PUB-ID

Zitieren

Talon S, De Luca A, De Bellis M, et al. Increased rigidity of the chiral centre of tocainide favours stereoselectivity and use-dependent block of skeletal muscle Na+ channels enhancing the antimyotonic activity in vivo. BRITISH JOURNAL OF PHARMACOLOGY. 2001;134(7):1523-1531.
Talon, S., De Luca, A., De Bellis, M., Desaphy, J. F., Lentini, G., Scilimati, A., Corbo, F., et al. (2001). Increased rigidity of the chiral centre of tocainide favours stereoselectivity and use-dependent block of skeletal muscle Na+ channels enhancing the antimyotonic activity in vivo. BRITISH JOURNAL OF PHARMACOLOGY, 134(7), 1523-1531. doi:10.1038/sj.bjp.0704366
Talon, S., De Luca, A., De Bellis, M., Desaphy, J. F., Lentini, G., Scilimati, A., Corbo, F., Franchini, C., Tortorella, P., Jockusch, H., et al. (2001). Increased rigidity of the chiral centre of tocainide favours stereoselectivity and use-dependent block of skeletal muscle Na+ channels enhancing the antimyotonic activity in vivo. BRITISH JOURNAL OF PHARMACOLOGY 134, 1523-1531.
Talon, S., et al., 2001. Increased rigidity of the chiral centre of tocainide favours stereoselectivity and use-dependent block of skeletal muscle Na+ channels enhancing the antimyotonic activity in vivo. BRITISH JOURNAL OF PHARMACOLOGY, 134(7), p 1523-1531.
S. Talon, et al., “Increased rigidity of the chiral centre of tocainide favours stereoselectivity and use-dependent block of skeletal muscle Na+ channels enhancing the antimyotonic activity in vivo”, BRITISH JOURNAL OF PHARMACOLOGY, vol. 134, 2001, pp. 1523-1531.
Talon, S., De Luca, A., De Bellis, M., Desaphy, J.F., Lentini, G., Scilimati, A., Corbo, F., Franchini, C., Tortorella, P., Jockusch, H., Camerino, D.C.: Increased rigidity of the chiral centre of tocainide favours stereoselectivity and use-dependent block of skeletal muscle Na+ channels enhancing the antimyotonic activity in vivo. BRITISH JOURNAL OF PHARMACOLOGY. 134, 1523-1531 (2001).
Talon, S, De Luca, A, De Bellis, M, Desaphy, JF, Lentini, G, Scilimati, A, Corbo, F, Franchini, C, Tortorella, P, Jockusch, Harald, and Camerino, DC. “Increased rigidity of the chiral centre of tocainide favours stereoselectivity and use-dependent block of skeletal muscle Na+ channels enhancing the antimyotonic activity in vivo”. BRITISH JOURNAL OF PHARMACOLOGY 134.7 (2001): 1523-1531.

9 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

Increased sodium channel use-dependent inhibition by a new potent analogue of tocainide greatly enhances in vivo antimyotonic activity.
De Bellis M, Carbonara R, Roussel J, Farinato A, Massari A, Pierno S, Muraglia M, Corbo F, Franchini C, Carratù MR, De Luca A, Conte Camerino D, Desaphy JF., Neuropharmacology 113(pt a), 2017
PMID: 27743929
Dual Action of Mexiletine and Its Pyrroline Derivatives as Skeletal Muscle Sodium Channel Blockers and Anti-oxidant Compounds: Toward Novel Therapeutic Potential.
De Bellis M, Sanarica F, Carocci A, Lentini G, Pierno S, Rolland JF, Conte Camerino D, De Luca A., Front Pharmacol 8(), 2017
PMID: 29379434
Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery.
Imbrici P, Liantonio A, Camerino GM, De Bellis M, Camerino C, Mele A, Giustino A, Pierno S, De Luca A, Tricarico D, Desaphy JF, Conte D., Front Pharmacol 7(), 2016
PMID: 27242528
Combined modifications of mexiletine pharmacophores for new lead blockers of Na(v)1.4 channels.
De Bellis M, De Luca A, Desaphy JF, Carbonara R, Heiny JA, Kennedy A, Carocci A, Cavalluzzi MM, Lentini G, Franchini C, Camerino DC., Biophys J 104(2), 2013
PMID: 23442856
Searching for novel anti-myotonic agents: pharmacophore requirement for use-dependent block of skeletal muscle sodium channels by N-benzylated cyclic derivatives of tocainide.
De Luca A, De Bellis M, Corbo F, Franchini C, Muraglia M, Catalano A, Carocci A, Camerino DC., Neuromuscul Disord 22(1), 2012
PMID: 21802953
Synthesis and in vitro sodium channel blocking activity evaluation of novel homochiral mexiletine analogs.
Carocci A, Catalano A, Bruno C, Lentini G, Franchini C, De Bellis M, De Luca A, Conte Camerino D., Chirality 22(3), 2010
PMID: 19544349
Constrained analogues of tocainide as potent skeletal muscle sodium channel blockers towards the development of antimyotonic agents.
Catalano A, Carocci A, Corbo F, Franchini C, Muraglia M, Scilimati A, De Bellis M, De Luca A, Camerino DC, Sinicropi MS, Tortorella V., Eur J Med Chem 43(11), 2008
PMID: 18342401
New potent mexiletine and tocainide analogues evaluated in vivo and in vitro as antimyotonic agents on the myotonic ADR mouse.
De Luca A, Pierno S, Liantonio A, Desaphy JF, Natuzzi F, Didonna MP, Ferrannini E, Jockusch H, Franchini C, Lentini G, Corbo F, Tortorella V, Camerino DC., Neuromuscul Disord 14(7), 2004
PMID: 15210163
Inhibition of skeletal muscle sodium currents by mexiletine analogues: specific hydrophobic interactions rather than lipophilia per se account for drug therapeutic profile.
De Luca A, Talon S, De Bellis M, Desaphy JF, Franchini C, Lentini G, Catalano A, Corbo F, Tortorella V, Conte-Camerino D., Naunyn Schmiedebergs Arch Pharmacol 367(3), 2003
PMID: 12644906

33 References

Daten bereitgestellt von Europe PubMed Central.

Action potentials reconstructed in normal and myotonic muscle fibres.
Adrian RH, Marshall MW., J. Physiol. (Lond.) 258(1), 1976
PMID: 940049
From mutation to myotonia in sodium channel disorders.
Cannon SC., Neuromuscul. Disord. 7(4), 1997
PMID: 9196906
Common modes of drug action on Na channels: local anesthesics, antiarrhythmics and anticonvulsants
CATTERALL W.A.., 1987
Antimyotonic effects of tocainide enantiomers on skeletal muscle fibers of congenitally myotonic goats.
Camerino DC, Pierno S, De Luca A, Bryant SH., Neuromuscul. Disord. 10(3), 2000
PMID: 10734261
Ion channel genes and human neurological disease: recent progress, prospects, and challenges.
Cooper EC, Jan LY., Proc. Natl. Acad. Sci. U.S.A. 96(9), 1999
PMID: 10220366
Molecular determinants of mexiletine structure for potent and use-dependent block of skeletal muscle sodium channels.
De Luca A, Natuzzi F, Desaphy JF, Loni G, Lentini G, Franchini C, Tortorella V, Camerino DC., Mol. Pharmacol. 57(2), 2000
PMID: 10648636
Inhibition of frog skeletal muscle sodium channels by newly synthesized chiral derivatives of mexiletine and tocainide.
De Luca A, Natuzzi F, Falcone G, Duranti A, Lentini G, Franchini C, Tortorella V, Camerino DC., Naunyn Schmiedebergs Arch. Pharmacol. 356(6), 1997
PMID: 9453464
Stereoselective effects of mexiletine enantiomers on sodium currents and excitability characteristics of adult skeletal muscle fibers.
De Luca A, Natuzzi F, Lentini G, Franchini C, Tortorella V, Conte Camerino D., Naunyn Schmiedebergs Arch. Pharmacol. 352(6), 1995
PMID: 9053738
Evaluation of the antimyotonic activity of mexiletine and some new analogs on sodium currents of single muscle fibers and on the abnormal excitability of the myotonic ADR mouse.
De Luca A, Pierno S, Natuzzi F, Franchini C, Duranti A, Lentini G, Tortorella V, Jockusch H, Camerino DC., J. Pharmacol. Exp. Ther. 282(1), 1997
PMID: 9223544
The different use dependences of tocainide and benzocaine are correlated with different effects on sodium channel inactivation.
DeLuca A, Probstle T, Brinkmeier H, Rudel R., Naunyn Schmiedebergs Arch. Pharmacol. 344(5), 1991
PMID: 1667329
Increased hindrance on the chiral carbon atom of mexiletine enhances the block of rat skeletal muscle Na+ channels in a model of myotonia induced by ATX.
Desaphy JF, Conte Camerino D, Franchini C, Lentini G, Tortorella V, De Luca A., Br. J. Pharmacol. 128(6), 1999
PMID: 10578128
AM1: a new general purpose quantum mechanical molecular model
DEWAR M.J.S., ZOEBISCH E.G., HEALY E.F., STEWART J.J.P.., 1985
Inactivation of human sodium channels and the effect of tocainide
FAKLER B., RUPPERSBERG J.P., SPITTELMEISTER W., RÜDEL R.., 1990
Synthesis of new 2,6-prolylxylidide analogues of tocainide as stereoselective blockers of voltage-gated Na(+) channels with increased potency and improved use-dependent activity.
Franchini C, Corbo F, Lentini G, Bruno G, Scilimati A, Tortorella V, Conte Camerino D, De Luca A., J. Med. Chem. 43(20), 2000
PMID: 11020295
Nonsense and missense mutations in the muscular chloride channel gene Clc-1 of myotonic mice
GRONEMEIER M., CONDIE A., PROSSER J., STEINMEYER K., JENTSCH T.J., JOCKUSCH H.., 1994
An improved vaseline gap voltage clamp for skeletal muscle fibers.
Hille B, Campbell DT., J. Gen. Physiol. 67(3), 1976
PMID: 1083424
Treatment of myotonia with antiarrhythmic drugs.
Kwiecinski H, Ryniewicz B, Ostrzycki A., Acta Neurol. Scand. 86(4), 1992
PMID: 1455983
Molecular pathophysiology of voltage-gated ion channels.
Lehmann-Horn F, Rudel R., Rev. Physiol. Biochem. Pharmacol. 128(), 1996
PMID: 8791722
The familial periodic paralyses and nondystrophic myotonias
PTÁCEK L.J.., 1998
Tocainide therapy in muscle cramps and spasms due to neuromuscular disease.
Puniani TS, Bertorini TE., Muscle Nerve 14(3), 1991
PMID: 1904131
Molecular determinants of state-dependent block of Na+ channels by local anesthetics.
Ragsdale DS, McPhee JC, Scheuer T, Catterall WA., Science 265(5179), 1994
PMID: 8085162
Common molecular determinants of local anesthetic, antiarrhythmic, and anticonvulsant block of voltage-gated Na+ channels.
Ragsdale DS, McPhee JC, Scheuer T, Catterall WA., Proc. Natl. Acad. Sci. U.S.A. 93(17), 1996
PMID: 8799190
Drug therapy. Tocainide.
Roden DM, Woosley RL., N. Engl. J. Med. 315(1), 1986
PMID: 3086724
The non-dystrophic myotonias
RÜDEL R., LEHMANN-HORN F., RICKER K.., 1994
Stereoselective interaction of tocainide and its chiral analogs with the sodium channels in human myoballs
TRICARICO D., FAKLER B., SPITTELMEISTER W., RUPPERSBERG J.-P., STUTZEL R., FRANCHINI C., TORTORELLA V., CONTE D., RÜDEL R.., 1991
Molecular determinants of voltage-dependent gating and binding of pore-blocking drugs in transmembrane segment IIIS6 of the Na(+) channel alpha subunit.
Yarov-Yarovoy V, Brown J, Sharp EM, Clare JJ, Scheuer T, Catterall WA., J. Biol. Chem. 276(1), 2001
PMID: 11024055

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 11724759
PubMed | Europe PMC

Suchen in

Google Scholar